Type I diabetes is a chronic autoimmune disease that occurs when the body's immune system destroys insulin producing pancreatic beta cells, resulting in insulin deficiency and hyperglycemia.
Current treatments for type I diabetes focus on controlling blood sugar with insulin therapy and must continue throughout a person's life.
Thomas Burris, chair of pharmacological and physiological science at Saint Louis University, and his research team focused on blocking the autoimmune process that destroys beta cells and leads to diabetes, with the aim of developing therapies that can prevent the illness from developing rather than treating its symptoms.
"We believe this type of treatment would slow the progression of type I diabetes in people or potentially even eliminate the need for insulin therapy," he said.
Scientists already knew that at least two types of immune "T-cells" contribute to the development of type I diabetes. However, the role of a third type, TH17, remained unclear.
In this study, researchers found that two nuclear receptors play critical roles in the development of TH17 cells, and that by targeting these receptors, they were able to stop autoimmunity from developing in several mouse models, sparing beta cells.
These results confirmed that TH17 cells likely play a key role in the development of type I diabetes and suggest that the use of drugs that target this cell type may offer a new treatment for the illness.
The research was published in the journal Endocrinology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
